Asia Pacific Radiopharmaceuticals Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Diagnostic Nuclear Medicine and Therapeutic Nuclear Medicine), Application (Oncology, Cardiology, Neurology, and Others), and End User (Hospitals, Imaging Centers, Academic and Research Centers, and Others)
Market Introduction
APAC consists of five major countries namely China, Japan, India, Australia, and South Korea. The market is also evaluated for the rest of countries in Asia Pacific. Japan led the market during forecast period. During the recent years, Japan has been increasing its focus towards the field of nuclear medicine. Japan has entered the era of the fastest growing geriatric population; the growing ageing population has led to the transformation of the medical systems. For instance, as per the World Economic Forum, currently, there are 2.3 billion people in their 70s in Japan. The advanced health transition is seen in the country and is increasingly putting pressure on the sustainability of its health systems. The rise in the geriatric population is responsible for increasing the burden of diseases in the region. The government organizations and research institutes are involved in the manufacturing of radiopharmaceuticals. For instance, Dept. of Radiopharmaceuticals Development, a part of National Institute of Radiological Sciences, aims to develop radiopharmaceuticals that are useful for clinical diagnosis and treatment, developing new radio nuclides required for synthesizing drugs, and manufacturing labeling techniques. Soaring growth in emerging countries and rising use of nuclear medicines for personalized treatment are the major factor driving the growth of the APAC radiopharmaceuticals market.
In case of COVID-19, APAC is highly affected especially India. The medical practices in the region continue to adapt to the challenges of COVID-19. On the one hand, healthcare professionals are responding to the pandemic, and on the other, it ensures minimal disruption to non-COVID-related procedures and hospitalizations. Hospitals and other healthcare facilities worldwide are forced to postpone elective procedures, such as surgeries. Most non-urgent therapies have been postponed. The COVID-19 pandemic affected health care services in many dimensions, starting from interrupting the regular patient flow to health care facilities, stressing, and overwhelming the health care resources, and leading to the implementation of extra protective measures and social distancing with increased utilization of telehealth and virtual medicine. As a precautionary approach, oncology practices implemented specific measures to reduce the number of patients in outpatient clinics, reduce unnecessary or elective procedures, and discharge patients from inpatient services. This has negatively impacted the growth of the radiopharmaceuticals market in the region. In addition, market players have also been affected by the pandemic owing to supply chain contrarians and reduced demand. The Specialty Pharma segment, especially radiopharma, was impacted due to COVID-19 and competition in radiopharma. Even before the pandemic, Nuclear Medicine’s supply chain was highly complex, depending on the availability of raw materials, manufacturing facilities' operations, and air transportation reliability. Thus, the factors mentioned above are negatively impacting the radiopharmaceuticals market in the region.
Get more information on this report :
Market Overview and Dynamics
The APAC radiopharmaceuticals market is expected to grow from US$ 1,384.59 million in 2021 to US$ 2,661.38 million by 2028; it is estimated to grow at a CAGR of 9.8% from 2021 to 2028. The Targeted alpha therapy (TAT) is the latest and evolving technique used for local and systemic cancer treatment. Preclinical research and clinical trials prove that alpha-emitting radionuclides kill targeted cancer cells and do not harm the healthy cells (selective cytotoxicity). 211At, 213Bi, 225Ac, and 227Th are among the alpha-emitting radioisotopes used to label targeting vectors such as monoclonal antibodies; the monoclonal antibodies labeled with α-emitting radionuclides are emerging as an effective radioimmunotherapy. Shorter-range radioisotopes (α particles) are used for treating patients with hematological cancer. Alpha radiations are suitable for killing isolated cancer cells in the vascular and lymphatic systems as well as in regressing tumors by disturbing tumor capillary networks for targeting and killing tumor capillary endothelial cells (ECs). The Radium-223 dichloride alpha therapy is the only approved concept for internal alpha-emitting radioisotope cancer treatment. The decay of radioactive elements after reaching the malignant tissue releases tumor-destroying radiations without causing significant damage to the adjoining healthy tissues. The alpha radiations are much localized, and they penetrate a maximum of 2–10 cell layers. Healthy cells in the surrounding tissue can recover from any damage caused by the radiation to a certain extent themselves. Nuclear imaging uses gamma emitters that have a long lifespan, which allows blood clearance as the tumor increases its uptake of the conjugate over time, so improving contrast. Nuclear imaging agents allow the diagnosis of tumor and organs. In addition, the rise in awareness about alpha radioimmunotherapy and surge in the availability of therapies for cancer treatment procedures are propelling the demand for nuclear imaging. Thus, the preferred use of alpha radioimmunotherapy in the treatment of cancer is fueling the APAC radiopharmaceuticals market growth.
Key Market Segments
In terms of type, the diagnostic nuclear medicine segment accounted for the largest share of the APAC radiopharmaceuticals market in 2020. In terms of application, the oncology segment held a larger market share of the APAC radiopharmaceuticals market in 2020. Further, the hospitals segment held a larger share of the APAC radiopharmaceuticals market based on end user in 2020.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the APAC radiopharmaceuticals market are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Advanced Accelerator Applications; Bayer AG; Bracco Imaging S.p.A; Cardinal Health Inc; Curium; ECZACIBA?I MONROL NUCLEAR PRODUCTS CO.; GENERAL ELECTRIC; Lantheus Medical Imaging, Inc.; Nordion; and NTP RADIOISOTOPES.
Reasons to buy report
- To understand the APAC radiopharmaceuticals market landscape and identify market segments that are most likely to guarantee a strong return
- Stay ahead of the race by comprehending the ever-changing competitive landscape for APAC radiopharmaceuticals market
- Efficiently plan M&A and partnership deals in APAC radiopharmaceuticals market by identifying market segments with the most promising probable sales
- Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form APAC radiopharmaceuticals market
- Obtain market revenue forecast for market by various segments from 2021-2028 in APAC region.
APAC Radiopharmaceuticals Market Segmentation
APAC Radiopharmaceuticals Market - By Type
- Diagnostic Nuclear Medicine
- SPECT
- PET
- Therapeutic Nuclear Medicine
- Alpha Emitters
- Beta Emitters
- Brachytherapy Isotopes
APAC Radiopharmaceuticals Market - By Application
- Oncology
- Cardiology
- Neurology
- Others
APAC Radiopharmaceuticals Market - By End User
- Hospitals
- Imaging Centers
- Academic and Research Centers
- Others
APAC Radiopharmaceuticals Market - By Country
- Japan
- China
- India
- Australia
- South Korea
- Rest of APAC
APAC Radiopharmaceuticals Market - Company Profiles
- Advanced Accelerator Applications
- Bayer AG
- Bracco Imaging S.p.A
- Cardinal Health Inc
- Curium
- ECZACIBA?I MONROL NUCLEAR PRODUCTS CO.
- GENERAL ELECTRIC
- Lantheus Medical Imaging, Inc.
- Nordion
- NTP RADIOISOTOPES
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 APAC Radiopharmaceuticals Market – By Type
1.3.2 APAC Radiopharmaceuticals Market – By Application
1.3.3 APAC Radiopharmaceuticals Market – By End User
1.3.4 APAC Radiopharmaceuticals Market– By Country
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. APAC Radiopharmaceuticals Market– Market Landscape
4.1 Overview
4.2 APAC PEST Analysis
4.3 Experts Opinion
5. APAC Radiopharmaceuticals Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Surging Use of Alpha Radio Immunotherapy for Cancer Treatment
5.1.2 Escalating Advancements in Nuclear Imaging Techniques
5.2 Market Restraints
5.2.1 Presence of Alternatives
5.3 Market Opportunities
5.3.1 Soaring Growth in Emerging Countries
5.4 Future Trends
5.4.1 Rising Use of Nuclear Medicines for Personalized Treatment
5.5 Impact Analysis
6. Radiopharmaceuticals Market– APAC Analysis
6.1 APAC Radiopharmaceuticals Market Revenue Forecast and Analysis
7. APAC Radiopharmaceuticals Market Analysis – By Type
7.1 Overview
7.2 APAC Radiopharmaceuticals Market Revenue Share, by Type (2021 and 2028)
7.3 Diagnostic Nuclear Medicine
7.3.1 Overview
7.3.2 Diagnostic Nuclear Medicine: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.3.3 SPECT
7.3.3.1 Overview
7.3.3.2 SPECT: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.3.4 PET
7.3.4.1 Overview
7.3.4.2 PET: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Therapeutic Nuclear Medicine
7.4.1 Overview
7.4.2 Therapeutic Nuclear Medicine: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.4.3 Alpha Emitters
7.4.3.1 Overview
7.4.3.2 Alpha Emitters: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.4.4 Beta Emitters
7.4.4.1 Overview
7.4.4.2 Beta Emitters: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.4.5 Brachytherapy Isotopes
7.4.5.1 Overview
7.4.5.2 Brachytherapy Isotopes: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
8. APAC Radiopharmaceuticals Market Analysis – By Application
8.1 Overview
8.2 APAC Radiopharmaceuticals Market Revenue Share, by Application (2021 and 2028)
8.3 Oncology
8.3.1 Overview
8.3.2 Oncology: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Cardiology
8.4.1 Overview
8.4.2 Cardiology: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
8.5 Neurology
8.5.1 Overview
8.5.2 Neurology: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9. APAC Radiopharmaceuticals Market Analysis – By End User
9.1 Overview
9.2 APAC Radiopharmaceuticals Market Share, by End User, 2021 and 2028, (%)
9.3 Hospitals
9.3.1 Overview
9.3.2 Hospitals: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.4 Imaging Centres
9.4.1 Overview
9.4.2 Imaging Centres: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.5 Academic and Research Centers
9.5.1 Overview
9.5.2 Academic and Research Centers: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.6 Others
9.6.1 Overview
9.6.2 Others: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
10. APAC Radiopharmaceuticals Market – Country Analysis
10.1 APAC: Radiopharmaceuticals Market
10.1.1 Overview
10.1.2 APAC: Radiopharmaceuticals Market, by Country, 2021 & 2028 (%)
10.1.2.1 China: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.1.1 China: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.1.2 China: Radiopharmaceuticals Market, By Type, 2019–2028 (USD Million)
10.1.2.1.2.1 China: Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine, 2019–2028 (USD Million)
10.1.2.1.2.2 China: Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine, 2019–2028 (USD Million)
10.1.2.1.3 China: Radiopharmaceuticals Market, by Application, 2019–2028 (USD Million)
10.1.2.1.4 China: Radiopharmaceuticals Market, by End User, 2019–2028 (USD Million)
10.1.2.2 Japan: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.2.1 Japan: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.2.2 Japan: Radiopharmaceuticals Market, By Type, 2019–2028 (USD Million)
10.1.2.2.2.1 Japan: Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine, 2019–2028 (USD Million)
10.1.2.2.2.2 Japan: Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine, 2019–2028 (USD Million)
10.1.2.2.3 Japan: Radiopharmaceuticals Market, by Application, 2019–2028 (USD Million)
10.1.2.2.4 Japan: Radiopharmaceuticals Market, by End User, 2019–2028 (USD Million)
10.1.2.3 India: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.3.1 India: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.3.2 India: Radiopharmaceuticals Market, By Type, 2019–2028 (USD Million)
10.1.2.3.2.1 India: Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine, 2019–2028 (USD Million)
10.1.2.3.2.2 India: Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine, 2019–2028 (USD Million)
10.1.2.3.3 India: Radiopharmaceuticals Market, by Application, 2019–2028 (USD Million)
10.1.2.3.4 India: Radiopharmaceuticals Market, by End User, 2019–2028 (USD Million)
10.1.2.4 Australia: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.4.1 Australia: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.4.2 Australia: Radiopharmaceuticals Market, By Type, 2019–2028 (USD Million)
10.1.2.4.2.1 Australia: Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine, 2019–2028 (USD Million)
10.1.2.4.2.2 Australia: Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine, 2019–2028 (USD Million)
10.1.2.4.3 Australia: Radiopharmaceuticals Market, by Application, 2019–2028 (USD Million)
10.1.2.4.4 Australia: Radiopharmaceuticals Market, by End User, 2019–2028 (USD Million)
10.1.2.5 South Korea: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.5.1 South Korea: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.5.2 South Korea: Radiopharmaceuticals Market, By Type, 2019–2028 (USD Million)
10.1.2.5.2.1 South Korea: Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine, 2019–2028 (USD Million)
10.1.2.5.2.2 South Korea: Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine, 2019–2028 (USD Million)
10.1.2.5.3 South Korea: Radiopharmaceuticals Market, by Application, 2019–2028 (USD Million)
10.1.2.5.4 South Korea: Radiopharmaceuticals Market, by End User, 2019–2028 (USD Million)
10.1.2.6 Rest of APAC: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.6.1 Rest of APAC: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.6.2 Rest of APAC: Radiopharmaceuticals Market, By Type, 2019–2028 (USD Million)
10.1.2.6.2.1 Rest of APAC: Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine, 2019–2028 (USD Million)
10.1.2.6.2.2 Rest of APAC: Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine, 2019–2028 (USD Million)
10.1.2.6.3 Rest of APAC: Radiopharmaceuticals Market, by Application, 2019–2028 (USD Million)
10.1.2.6.4 Rest of APAC: Radiopharmaceuticals Market, by End User, 2019–2028 (USD Million)
11. Impact Of COVID-19 Pandemic on APAC Radiopharmaceuticals Market
11.1 APAC: Impact Assessment of COVID-19 Pandemic
12. Industry Landscape
12.1 Overview
12.2 Inorganic Growth Strategies
12.2.1 Overview
12.3 Organic Growth Strategies
12.3.1 Overview
13. Company Profiles
13.1 Cardinal Health Inc
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Curium
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 GENERAL ELECTRIC
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Lantheus Medical Imaging, Inc.
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Bayer AG
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Bracco Imaging S.p.A
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 ECZACIBAI MONROL NUCLEAR PRODUCTS CO.
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Nordion
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 NTP RADIOISOTOPES
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Advanced Accelerator Applications
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. Appendix
14.1 About The Insight Partners
14.2 Glossary of Terms
LIST OF TABLES
Table 1. APAC Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
Table 2. China: Radiopharmaceuticals Market, By Type – Revenue and Forecast to 2028 (USD Million)
Table 3. China Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)
Table 4. China Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)
Table 5. China: Radiopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (USD Million)
Table 6. China: Radiopharmaceuticals Market, by End User– Revenue and Forecast to 2028 (USD Million)
Table 7. Japan: Radiopharmaceuticals Market, By Type– Revenue and Forecast to 2028 (USD Million)
Table 8. Japan Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)
Table 9. Japan Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)
Table 10. Japan: Radiopharmaceuticals Market, by Application– Revenue and Forecast to 2028 (USD Million)
Table 11. Japan: Radiopharmaceuticals Market, by End User – Revenue and Forecast to 2028 (USD Million)
Table 12. India: Radiopharmaceuticals Market, By Type – Revenue and Forecast to 2028 (USD Million)
Table 13. India Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)
Table 14. India Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)
Table 15. India: Radiopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (USD Million)
Table 16. India: Radiopharmaceuticals Market, by End User– Revenue and Forecast to 2028 (USD Million)
Table 17. Australia: Radiopharmaceuticals Market, By Type – Revenue and Forecast to 2028 (USD Million)
Table 18. Australia Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)
Table 19. Australia Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)
Table 20. Australia: Radiopharmaceuticals Market, by Application– Revenue and Forecast to 2028 (USD Million)
Table 21. Australia: Radiopharmaceuticals Market, by End User– Revenue and Forecast to 2028 (USD Million)
Table 22. South Korea: Radiopharmaceuticals Market, By Type – Revenue and Forecast to 2028 (USD Million)
Table 23. South Korea Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)
Table 24. South Korea Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)
Table 25. South Korea: Radiopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (USD Million)
Table 26. South Korea: Radiopharmaceuticals Market, by End User– Revenue and Forecast to 2028 (USD Million)
Table 27. Rest of APAC: Radiopharmaceuticals Market, By Type – Revenue and Forecast to 2028 (USD Million)
Table 28. Rest of APAC Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)
Table 29. Rest of APAC Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)
Table 30. Rest of APAC: Radiopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (USD Million)
Table 31. Rest of APAC: Radiopharmaceuticals Market, by End User– Revenue and Forecast to 2028 (USD Million)
Table 32. Recent Inorganic Growth Strategies
Table 33. Recent Organic Growth Strategies
Table 34. Glossary of Terms
LIST OF FIGURES
Figure 1. APAC Radiopharmaceuticals Market Segmentation
Figure 2. APAC Radiopharmaceuticals Market Segmentation, By Country
Figure 3. APAC Radiopharmaceuticals Market Overview
Figure 4. Diagnostic Nuclear Medicine Segment Held the Largest Share of the Market in 2021
Figure 5. India to Show Significant Growth During Forecast Period
Figure 6. APAC PEST Analysis
Figure 7. APAC Radiopharmaceuticals Market Impact Analysis of Drivers and Restraints
Figure 8. APAC Radiopharmaceuticals Market– Revenue Forecast and Analysis
Figure 9. APAC Radiopharmaceuticals Market Revenue Share, by Type (2021 and 2028)
Figure 10. APAC Diagnostic Nuclear Medicine: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 11. APAC SPECT: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 12. APAC PET: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 13. APAC Therapeutic Nuclear Medicine: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 14. APAC Alpha Emitters: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 15. APAC Beta Emitters: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 16. APAC Brachytherapy Isotopes: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 17. APAC Radiopharmaceuticals Market Revenue Share, by Application (2021 and 2028)
Figure 18. APAC Oncology: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 19. APAC Cardiology: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 20. APAC Neurology: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 21. APAC Others: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 22. APAC Radiopharmaceuticals Market Share, by End User, 2021 and 2028 (%)
Figure 23. APAC Hospitals: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 24. APAC Imaging Centres: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 25. APAC Academic and Research Centers: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 26. APAC Others: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 27. APAC: Radiopharmaceuticals Market, by Key Country – Revenue (2021) (USD Million)
Figure 28. APAC: Radiopharmaceuticals Market, by Country, 2021 & 2028 (%)
Figure 29. China: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
Figure 30. Japan: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
Figure 31. India: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
Figure 32. Australia: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
Figure 33. South Korea: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
Figure 34. Rest of APAC: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
Figure 35. Impact of COVID-19 Pandemic in APAC Country Markets
- Advanced Accelerator Applications
- Bayer AG
- Bracco Imaging S.p.A
- Cardinal Health Inc
- Curium
- ECZACIBAI MONROL NUCLEAR PRODUCTS CO.
- GENERAL ELECTRIC
- Lantheus Medical Imaging, Inc.
- Nordion
- NTP RADIOISOTOPES
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the APAC radiopharmaceuticals market.
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the APAC radiopharmaceuticals market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth APAC market trends and outlook coupled with the factors driving the radiopharmaceuticals market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution